Declaration of conformity drawn up for Inbiomotion MAFTEST®
The MAFTEST® was originally developed by Inbiomotion SL, and now Kreatech Biotechnology B.V (subsidiary of Leica Biosystems). completed the conformity assessment and drew up the declaration of conformity for in vitro medical devices.
The MAFTEST® was originally developed by Inbiomotion SL, and now Kreatech Biotechnology B.V (subsidiary of Leica Biosystems). completed the conformity assessment and drew up the declaration of conformity for in vitro medical devices.
The MAFTEST® or more precisely, the Kreatech™ MAF (16q23) / D16Z3 FISH probe, as mentioned in the declaration of conformity, will soon be commercialized in the member states of the European Union.
The MAFTEST® is intended to detect in the tumor the amplification involving the MAF gene region in order to determine the risk in early-stage breast cancer patients.
